AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

PureTech Health plc

119.8p -$4.80 (-3.85%)
LSE · 15 Sep 2026 15:35 UTC
Previous Close
119.4p
Day Range
118.4p123.8p
Year Range
104.71p143.6p
Market Cap
291.61M
AVG Volume
603.05K
Trailing/Forward PE
-/-
PEG ratio
-
Dividend Yield
-
Next Earnings Date
2026-09-22
Primary Exchange
London Stock ExchangeUK
Revenue (USD)
05M10M15M21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Revenue (USD) by quarter
PeriodRevenue (USD)
25 Q42.82M
25 Q21.85M
24 Q44.03M
24 Q2288K
23 Q4180K
23 Q23.15M
22 Q48.59M
22 Q27.03M
21 Q411.55M
21 Q25.84M
Net Income (USD)
-100M-50M050M100M21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Net Income (USD) by quarter
PeriodNet Income (USD)
25 Q4-65.45M
25 Q2-44.6M
24 Q495.28M
24 Q2-41.77M
23 Q4-40.69M
23 Q2-25M
22 Q4-22.01M
22 Q2-28.34M
21 Q414.84M
21 Q2-75.39M
Operating Income (USD)
-150M-100M-50M021 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Operating Income (USD) by quarter
PeriodOperating Income (USD)
25 Q4-50.84M
25 Q2-47.93M
24 Q4-69.7M
24 Q2-66.4M
23 Q4-70.04M
23 Q2-76.16M
22 Q4-96.61M
22 Q2-101.19M
21 Q4-82.2M
21 Q2-68.08M
EBITDA (USD)
-100M-50M050M100M150M21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L EBITDA (USD) by quarter
PeriodEBITDA (USD)
25 Q4-49.17M
25 Q2-46.24M
24 Q4101.97M
24 Q2-64.58M
23 Q4-68.56M
23 Q2-73.1M
22 Q4-95.06M
22 Q2-96.9M
21 Q4-80.61M
21 Q2-65.32M
Cash Flows (USD)
-100M-75M-50M-25M021 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Cash Flows (USD) by quarter
PeriodCash Flows (USD)
25 Q4-37.87M
25 Q2-45.94M
24 Q4-54.37M
24 Q2-80.01M
23 Q4-40.78M
23 Q2-65.2M
22 Q4-92.07M
22 Q2-88.9M
21 Q4-95.75M
21 Q2-68.09M
EPS (USD)
-0.4-0.200.20.421 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L EPS (USD) by quarter
PeriodEPS (USD)
25 Q4-0.27
25 Q2-0.19
24 Q40.35
24 Q2-0.15
23 Q4-0.15
23 Q2-0.09
22 Q4-0.08
22 Q2-0.1
21 Q40.05
21 Q2-0.26
Expenses (USD)
-50M050M100M150MR&DSG&ACapex21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Expenses (USD) by quarter
PeriodExpenses (USD)
25 Q452M
25 Q249.78M
24 Q415.1M
24 Q266.69M
23 Q470.22M
23 Q279.38M
22 Q4105.73M
22 Q2109.87M
21 Q496.6M
21 Q276.64M
Cash & Debt (USD)
0200M400M600MCashLong Term DebtShort Term Debt21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
25 Q4279M
25 Q2321.55M
24 Q4367.31M
24 Q2500.42M
23 Q4327.14M
23 Q2352.14M
22 Q4350.1M
22 Q2368.03M
21 Q4465.71M
21 Q2441.89M
Debt ratios
024621 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Debt ratios by quarter
PeriodDebt ratios
25 Q44.47
25 Q23.88
24 Q42
24 Q21.18
23 Q40.57
23 Q20.94
22 Q40.9
22 Q21.04
21 Q41.58
21 Q21.49
Margins
-30000%-20000%-10000%0%10000%21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Margins by quarter
PeriodMargins
25 Q441.03%
25 Q2-1245.22%
24 Q41066.67%
24 Q2-13416.67%
23 Q4-23838.33%
23 Q2-1587.17%
22 Q4-690.19%
22 Q2-1102.94%
21 Q4-1394.22%
21 Q2-728.14%
Return on Capital
-40%-20%0%20%40%21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Return on Capital by quarter
PeriodReturn on Capital
25 Q4-21.4%
25 Q2-12.09%
24 Q423.36%
24 Q2-13.64%
23 Q4-8.88%
23 Q2-4.91%
22 Q4-4.02%
22 Q2-4.92%
21 Q42.54%
21 Q2-13.43%
Shares Outstanding
0100M200M300M400M21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Shares Outstanding by quarter
PeriodShares Outstanding
25 Q4241.35M
25 Q2234.76M
24 Q4269.66M
24 Q2269.66M
23 Q4270.52M
23 Q2277.83M
22 Q4275.86M
22 Q2283.45M
21 Q4300.5M
21 Q2286.01M
Book Value Per Share (USD)
012321 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
25 Q41.27
25 Q21.57
24 Q41.51
24 Q21.14
23 Q41.69
23 Q21.83
22 Q41.99
22 Q22.03
21 Q41.94
21 Q21.96
Total Assets (USD)
0250M500M750M1B21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
PRTC.L Total Assets (USD) by quarter
PeriodTotal Assets (USD)
25 Q4534.9M
25 Q2553.24M
24 Q4602.63M
24 Q2579.95M
23 Q4693.97M
23 Q2693.55M
22 Q4702.65M
22 Q2823.15M
21 Q4946.01M
21 Q2896.88M
PureTech Health plc
PRTC.L
Stockpicker

Video analysis: PRTC.L

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: PRTC.L

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

gurufocus.com · 9 Sep 2026

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran

PureTech Health: Notice of Half-Yearly Results

gurufocus.com · 4 Sep 2026

PureTech Health: Notice of Half-Yearly Results

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended 30 June 2026 on Tu

Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (

gurufocus.com · 25 Aug 2026

Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (

Celea Therapeutics, Inc. ("Celea" or the "Company"), a clinical-stage biopharmaceutical company dedicated to advancing transformative treatments for people with

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

gurufocus.com · 25 Aug 2026

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

gurufocus.com · 2 Jul 2026

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tra

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.